BRPI0913939A2 - dose unitária de apadenoson - Google Patents

dose unitária de apadenoson

Info

Publication number: BRPI0913939A2
Authority: BR; Brazil
Prior art keywords: apadenoson; unit dose; dose; unit
Prior art date: 2008-07-03

Application number

BRPI0913939A

Other languages

English (en)

Inventor

Robert Hendel

Shannon P Williams

William B Stilley

Original Assignee

Univ Virginia Patent Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-07-03

Filing date

2009-07-02

Publication date

2016-04-26

2009-07-02 Application filed by Univ Virginia Patent Found filed Critical Univ Virginia Patent Found

2016-04-26 Publication of BRPI0913939A2 publication Critical patent/BRPI0913939A2/pt

Links

229950001316 apadenoson Drugs 0.000 title 1
FLEVIENZILQUKB-XTWQNQIISA-N chembl1950649 Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(C#CC[C@@H]3CC[C@H](CC3)C(=O)OC)=NC(N)=C2N=C1 FLEVIENZILQUKB-XTWQNQIISA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Inorganic Chemistry (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Dermatology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Toxicology (AREA)
Rheumatology (AREA)
Pathology (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Cardiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Saccharide Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)

BRPI0913939A 2008-07-03 2009-07-02 dose unitária de apadenoson BRPI0913939A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US7816908P	2008-07-03	2008-07-03
US15593709P	2009-02-27	2009-02-27
PCT/US2009/003939 WO2010002473A1 (en)	2008-07-03	2009-07-02	Unit dosage of apadenoson

Publications (1)

Publication Number	Publication Date
BRPI0913939A2 true BRPI0913939A2 (pt)	2016-04-26

Family

ID=41152021

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0913939A BRPI0913939A2 (pt)	2008-07-03	2009-07-02	dose unitária de apadenoson

Country Status (23)

Country	Link
US (6)	US20100003193A1 (pt)
EP (1)	EP2306971B1 (pt)
JP (2)	JP2011526894A (pt)
KR (2)	KR20110028531A (pt)
CN (1)	CN102119023B (pt)
AU (1)	AU2009266317B2 (pt)
BR (1)	BRPI0913939A2 (pt)
CA (1)	CA2729819C (pt)
CY (1)	CY1116283T1 (pt)
DK (1)	DK2306971T3 (pt)
EA (1)	EA022348B1 (pt)
ES (1)	ES2537069T3 (pt)
HR (1)	HRP20150454T1 (pt)
IL (2)	IL210428A (pt)
MX (1)	MX2011000193A (pt)
MY (1)	MY161655A (pt)
NZ (1)	NZ590489A (pt)
PL (1)	PL2306971T3 (pt)
PT (1)	PT2306971E (pt)
SI (1)	SI2306971T1 (pt)
SM (1)	SMT201500123B (pt)
WO (1)	WO2010002473A1 (pt)
ZA (1)	ZA201100163B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102119023B (zh)	2008-07-03	2014-04-09	弗吉尼亚大学专利基金会	阿帕地松单位剂量
CA2863685C (en)	2012-02-03	2020-10-13	Adenobio N.V.	A method of using adenosine and dipyridamole for pharmacologic stress testing, with specific compositions, unit dosage forms and kits
CN109020881B (zh) *	2018-06-28	2020-04-28	新发药业有限公司	一种阿帕替尼的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5091171B2 (en)	1986-12-23	1997-07-15	Tristrata Inc	Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
DE69120840T2 (de) *	1990-02-21	1996-11-21	United Kingdom Government	Supraleiter auf Thalliumbasis substituiert durch seltene Erden
IT1263831B (it)	1993-01-29	1996-09-04	Paolo Chiesi	Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
US6232297B1 (en) *	1999-02-01	2001-05-15	University Of Virginia Patent Foundation	Methods and compositions for treating inflammatory response
US7427606B2 (en)	1999-02-01	2008-09-23	University Of Virginia Patent Foundation	Method to reduce inflammatory response in transplanted tissue
CA2361614C (en) *	1999-02-01	2008-08-26	University Of Virginia Patent Foundation	Compositions for treating inflammatory response
US6322771B1 (en) *	1999-06-18	2001-11-27	University Of Virginia Patent Foundation	Induction of pharmacological stress with adenosine receptor agonists
WO2002034966A1 (en) *	2000-10-23	2002-05-02	National Institute Of Advanced Industrial Science And Technology	Composite structure and method and apparatus for manufacture thereof
US6620645B2 (en) *	2000-11-16	2003-09-16	G.T. Equipment Technologies, Inc	Making and connecting bus bars on solar cells
EP1434782A2 (en)	2001-10-01	2004-07-07	University of Virginia Patent Foundation	2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
EP1480998B1 (en) *	2002-02-27	2006-11-22	Ferring BV	Intermediates and methods for making heptapeptide oxytocin analogues
AU2003234716A1 (en) *	2002-04-10	2003-10-27	Joel M. Linden	Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases
US6662088B1 (en) *	2002-06-28	2003-12-09	General Electric Company	Methods and systems for inspecting aircraft fuselage frames
WO2005107463A1 (en)	2004-05-03	2005-11-17	University Of Virginia Patent Foundation	Agonists of a2a adenosine receptors for treatment of diabetic nephropathy
AU2005267706B2 (en) *	2004-08-02	2011-12-08	University Of Virginia Patent Foundation	2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
DE602005011111D1 (de)	2005-06-03	2009-01-02	St Microelectronics Srl	Selbstjustiertes Verfahren zur Herstellung von Phasenwechselspeicherzellen
US7767686B2 (en)	2006-03-03	2010-08-03	Covidien Ag	Method of using adenosine receptor blockers during tissue ablation
DE102006022450A1 (de)	2006-05-13	2007-11-15	Lanxess Deutschland Gmbh	Wässrige Rußdispersionen für Ink-Jet
CA2694983A1 (en) *	2007-07-17	2009-01-22	Combinatorx, Incorporated	Treatments of b-cell proliferative disorders
TW200905703A (en) *	2007-07-27	2009-02-01	Delta Electronics Inc	Magnetic device and manufacturing method thereof
CN102119023B (zh)	2008-07-03	2014-04-09	弗吉尼亚大学专利基金会	阿帕地松单位剂量

2009
- 2009-07-02 CN CN200980131395.6A patent/CN102119023B/zh not_active Expired - Fee Related
- 2009-07-02 KR KR1020117002495A patent/KR20110028531A/ko not_active Ceased
- 2009-07-02 CA CA2729819A patent/CA2729819C/en active Active
- 2009-07-02 EP EP09773926.2A patent/EP2306971B1/en active Active
- 2009-07-02 BR BRPI0913939A patent/BRPI0913939A2/pt not_active Application Discontinuation
- 2009-07-02 KR KR1020147003142A patent/KR20140021726A/ko not_active Withdrawn
- 2009-07-02 MX MX2011000193A patent/MX2011000193A/es active IP Right Grant
- 2009-07-02 EA EA201100132A patent/EA022348B1/ru not_active IP Right Cessation
- 2009-07-02 SI SI200931189T patent/SI2306971T1/sl unknown
- 2009-07-02 PT PT97739262T patent/PT2306971E/pt unknown
- 2009-07-02 PL PL09773926T patent/PL2306971T3/pl unknown
- 2009-07-02 NZ NZ590489A patent/NZ590489A/xx not_active IP Right Cessation
- 2009-07-02 WO PCT/US2009/003939 patent/WO2010002473A1/en not_active Ceased
- 2009-07-02 DK DK09773926.2T patent/DK2306971T3/en active
- 2009-07-02 AU AU2009266317A patent/AU2009266317B2/en not_active Ceased
- 2009-07-02 ES ES09773926.2T patent/ES2537069T3/es active Active
- 2009-07-02 MY MYPI2010006339A patent/MY161655A/en unknown
- 2009-07-02 HR HRP20150454TT patent/HRP20150454T1/hr unknown
- 2009-07-02 US US12/496,949 patent/US20100003193A1/en not_active Abandoned
- 2009-07-02 JP JP2011516343A patent/JP2011526894A/ja not_active Withdrawn
2011
- 2011-01-02 IL IL210428A patent/IL210428A/en not_active IP Right Cessation
- 2011-01-06 ZA ZA2011/00163A patent/ZA201100163B/en unknown
2012
- 2012-07-09 US US13/544,364 patent/US20130017153A1/en not_active Abandoned
2013
- 2013-08-29 JP JP2013177622A patent/JP2013237702A/ja active Pending
- 2013-12-11 US US14/103,130 patent/US9415058B2/en not_active Expired - Fee Related
2015
- 2015-05-14 CY CY20151100432T patent/CY1116283T1/el unknown
- 2015-05-22 SM SM201500123T patent/SMT201500123B/xx unknown
2016
- 2016-05-10 IL IL245577A patent/IL245577B/en active IP Right Grant
- 2016-06-13 US US15/181,235 patent/US9662406B2/en not_active Expired - Fee Related
2017
- 2017-05-19 US US15/600,303 patent/US20170252463A1/en not_active Abandoned
2018
- 2018-07-25 US US16/045,359 patent/US20190022253A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PL2306971T3 (pl)	2015-07-31
US9415058B2 (en)	2016-08-16
IL210428A0 (en)	2011-03-31
HRP20150454T1 (hr)	2015-06-19
CY1116283T1 (el)	2017-02-08
AU2009266317B2 (en)	2013-12-05
IL210428A (en)	2016-05-31
ES2537069T3 (es)	2015-06-02
US20100003193A1 (en)	2010-01-07
US9662406B2 (en)	2017-05-30
US20190022253A1 (en)	2019-01-24
EP2306971A1 (en)	2011-04-13
JP2013237702A (ja)	2013-11-28
US20130017153A1 (en)	2013-01-17
US20140100185A1 (en)	2014-04-10
SI2306971T1 (sl)	2015-07-31
CA2729819A1 (en)	2010-01-07
SMT201500123B (it)	2015-09-07
EA201100132A1 (ru)	2011-08-30
AU2009266317A1 (en)	2010-01-07
MY161655A (en)	2017-04-28
NZ590489A (en)	2013-01-25
MX2011000193A (es)	2011-03-24
US20170007722A1 (en)	2017-01-12
EA022348B1 (ru)	2015-12-30
US20170252463A1 (en)	2017-09-07
DK2306971T3 (en)	2015-05-11
CN102119023B (zh)	2014-04-09
KR20110028531A (ko)	2011-03-18
CN102119023A (zh)	2011-07-06
WO2010002473A1 (en)	2010-01-07
CA2729819C (en)	2014-08-26
EP2306971B1 (en)	2015-02-25
IL245577A0 (en)	2016-06-30
ZA201100163B (en)	2011-09-28
PT2306971E (pt)	2015-06-18
KR20140021726A (ko)	2014-02-20
IL245577B (en)	2019-05-30
JP2011526894A (ja)	2011-10-20
HK1156250A1 (en)	2012-06-08

Legal Events

Date	Code	Title	Description
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-10-09	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-10-01	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2020-08-11	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-10-27	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2021-02-09	B09B	Patent application refused [chapter 9.2 patent gazette]
2021-04-27	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL

Publication	Publication Date	Title
EP2296593A4 (en)	2015-01-14	MEDICAL HEAD COVER
BRPI1011587A2 (pt)	2016-03-22	compostos e composições terapèuticas
SMT201500186B (it)	2015-10-30	Autoanticorpi umani anti-alfa-sinucleina
EP2265283A4 (en)	2012-04-25	Auristatin-DRUG-LINKER CONJUGATES
EP2334277A4 (en)	2016-01-06	CRUTCH
BRPI0916931A2 (pt)	2015-11-24	agentes terapêuticos
BRPI0920521A2 (pt)	2018-01-16	combinação farmacêutica
BRPI0906366A2 (pt)	2015-07-07	Inalador
BRPI1005525A2 (pt)	2016-02-23	compostos de azaazuleno
DK2326651T3 (da)	2014-01-20	Buprenorphinanaloger
PT2260053E (pt)	2014-08-29	Análogos de oxitocina
DK3300729T3 (da)	2020-01-20	Terapeutiske sammensætninger indeholdende macitentan
EP2236149A4 (en)	2012-12-26	MEDICAL COMPOSITION
EP2110789A4 (en)	2010-12-01	PAPER MONEY PROCESSOR
BRPI0906367A2 (pt)	2016-04-26	inalador
DK2271618T3 (da)	2014-06-16	Farmaceutiske forbindelser
CU23884B1 (es)	2013-04-19	Derivados de dibenzotiazepina
HRP20160577T1 (hr)	2016-07-29	Liječenje osteoartritisa
BRPI0910931A2 (pt)	2019-09-24	ciclopentanos substituídos terapêuticos
BRPI0906369A2 (pt)	2015-07-07	Inalador
EP2309854A4 (en)	2012-06-06	ACCELERATED THERAPY:
SMT201500123B (it)	2015-09-07	Dosaggio unitario di apadenoson
BRPI0909764A2 (pt)	2015-10-06	compostos terapêuticos
BRPI1009199A2 (pt)	2016-03-08	compostos de pirazinoisoquinolina
BRPI0906879A2 (pt)	2015-07-07	Compostos terapêuticos